• Latest Posts
In Depth 26 Oct 2023

Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials

Biogen acquiring Reata Pharmaceuticals for $7.3B

FDA approves Alzheimer’s treatment

Biogen ALS drug gets FDA ok

9 neuroscience biotech companies you should know about


Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

More News! 29 Sep 2022

Positive results from Eisai and Biogen Alzheimer’s trial

FDA Approval of Biogen’s Drug Boosts European Alzheimer’s Space

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls